Cart
sales@molnova.com
CDK9-IN-1
CAS No. 1415559-43-1
CDK9-IN-1( —— )
Catalog No. M11724 CAS No. 1415559-43-1
CDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameCDK9-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays.
-
DescriptionCDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays.
-
In VitroCDK9-IN-1 is a potent CDK9 inhibitor that shows high activity against HIV-1 replication.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research AreaInfection
-
Indication——
Chemical Information
-
CAS Number1415559-43-1
-
Formula Weight499.541
-
Molecular FormulaC26H21N5O4S
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCC1=C(C=C(C=C1)NC2=NC=NC(=C2)C3=CC(=CC=C3)N4C(=O)C5=CC=CC=C5C4=O)NS(=O)(=O)C
-
Chemical NameN-(5-(6-(3-(1,3-dioxoisoindolin-2-yl)phenyl)pyrimidin-4-ylamino)-2-methylphenyl)methanesulfonamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Németh G, et al. Curr Med Chem. 2011;18(3):342-58.
molnova catalog
related products
-
NSC23005 sodium
A novel specific, effective p18 (p18INK4C) inhibitor that can selectively promote HSCs expansion with EC50 of 5.21 nM.
-
Senexin-A
A selective inhibitor of CDK8 (IC50=0.28 uM) and CDK19; inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 uM and 0.31 uM, respectively.
-
Ro-3306
RO-3306 is an ATP-competitive inhibitor, and inhibits CDK1/cyclin A complexes with Ki of 110 nM. RO-3306 blocks the cell cycle in the G2/M phase of human cancer cells.
